nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.191	0.5	CiPCiCtD
Regorafenib—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.191	0.5	CiPCiCtD
Regorafenib—RET—hematologic cancer	0.0424	0.201	CbGaD
Regorafenib—PDGFRB—hematologic cancer	0.0294	0.139	CbGaD
Regorafenib—PDGFRA—hematologic cancer	0.0286	0.136	CbGaD
Regorafenib—BRAF—hematologic cancer	0.0262	0.124	CbGaD
Regorafenib—ABL1—hematologic cancer	0.0262	0.124	CbGaD
Regorafenib—KIT—hematologic cancer	0.021	0.0996	CbGaD
Regorafenib—UGT1A1—hematologic cancer	0.0207	0.0981	CbGaD
Regorafenib—MAPK11—Nilotinib—hematologic cancer	0.0159	0.0634	CbGbCtD
Regorafenib—FGFR2—Thalidomide—hematologic cancer	0.0138	0.0552	CbGbCtD
Regorafenib—FRK—Nilotinib—hematologic cancer	0.0126	0.0504	CbGbCtD
Regorafenib—NTRK1—Imatinib—hematologic cancer	0.0116	0.0464	CbGbCtD
Regorafenib—ABCG2—hematologic cancer	0.0116	0.0552	CbGaD
Regorafenib—FRK—Dasatinib—hematologic cancer	0.0112	0.0445	CbGbCtD
Regorafenib—TEK—Nilotinib—hematologic cancer	0.0106	0.0422	CbGbCtD
Regorafenib—EPHA2—Nilotinib—hematologic cancer	0.0106	0.0422	CbGbCtD
Regorafenib—BRAF—Nilotinib—hematologic cancer	0.0106	0.0422	CbGbCtD
Regorafenib—RET—Ruxolitinib—hematologic cancer	0.00947	0.0378	CbGbCtD
Regorafenib—EPHA2—Dasatinib—hematologic cancer	0.00935	0.0373	CbGbCtD
Regorafenib—PDGFRA—Imatinib—hematologic cancer	0.00799	0.0319	CbGbCtD
Regorafenib—KIT—Imatinib—hematologic cancer	0.00799	0.0319	CbGbCtD
Regorafenib—PDGFRB—Imatinib—hematologic cancer	0.00727	0.029	CbGbCtD
Regorafenib—PDGFRA—Nilotinib—hematologic cancer	0.00726	0.0289	CbGbCtD
Regorafenib—KIT—Nilotinib—hematologic cancer	0.00726	0.0289	CbGbCtD
Regorafenib—PDGFRB—Nilotinib—hematologic cancer	0.00661	0.0263	CbGbCtD
Regorafenib—KIT—Dasatinib—hematologic cancer	0.00642	0.0256	CbGbCtD
Regorafenib—PDGFRA—Dasatinib—hematologic cancer	0.00642	0.0256	CbGbCtD
Regorafenib—PDGFRB—Dasatinib—hematologic cancer	0.00584	0.0233	CbGbCtD
Regorafenib—ABL1—Imatinib—hematologic cancer	0.00578	0.023	CbGbCtD
Regorafenib—ABL1—Nilotinib—hematologic cancer	0.00525	0.0209	CbGbCtD
Regorafenib—ABCB1—hematologic cancer	0.00484	0.023	CbGaD
Regorafenib—ABL1—Dasatinib—hematologic cancer	0.00464	0.0185	CbGbCtD
Regorafenib—ABCG2—Clofarabine—hematologic cancer	0.00294	0.0117	CbGbCtD
Regorafenib—UGT1A1—Nilotinib—hematologic cancer	0.00218	0.00869	CbGbCtD
Regorafenib—UGT1A9—Irinotecan—hematologic cancer	0.00183	0.0073	CbGbCtD
Regorafenib—ABCG2—Daunorubicin—hematologic cancer	0.00172	0.00687	CbGbCtD
Regorafenib—CYP2B6—Thiotepa—hematologic cancer	0.00171	0.00683	CbGbCtD
Regorafenib—UGT1A1—Irinotecan—hematologic cancer	0.0015	0.00597	CbGbCtD
Regorafenib—ABCG2—Teniposide—hematologic cancer	0.0015	0.00597	CbGbCtD
Regorafenib—ABCG2—Cladribine—hematologic cancer	0.00144	0.00572	CbGbCtD
Regorafenib—ABCG2—Imatinib—hematologic cancer	0.00132	0.00526	CbGbCtD
Regorafenib—UGT1A1—Etoposide—hematologic cancer	0.0012	0.00478	CbGbCtD
Regorafenib—ABCG2—Nilotinib—hematologic cancer	0.0012	0.00478	CbGbCtD
Regorafenib—CYP2C9—Bexarotene—hematologic cancer	0.00109	0.00435	CbGbCtD
Regorafenib—ABCG2—Dasatinib—hematologic cancer	0.00106	0.00422	CbGbCtD
Regorafenib—ABCB1—Lenalidomide—hematologic cancer	0.00106	0.00422	CbGbCtD
Regorafenib—ABCG2—Mitoxantrone—hematologic cancer	0.00105	0.00417	CbGbCtD
Regorafenib—CYP2B6—Ifosfamide—hematologic cancer	0.000972	0.00387	CbGbCtD
Regorafenib—CYP2C8—Bortezomib—hematologic cancer	0.00096	0.00382	CbGbCtD
Regorafenib—CYP2C9—Idarubicin—hematologic cancer	0.000905	0.00361	CbGbCtD
Regorafenib—CYP2B6—Nilotinib—hematologic cancer	0.000844	0.00336	CbGbCtD
Regorafenib—ABCG2—Irinotecan—hematologic cancer	0.000824	0.00329	CbGbCtD
Regorafenib—CYP2C19—Bortezomib—hematologic cancer	0.000805	0.00321	CbGbCtD
Regorafenib—FRK—hematopoietic system—hematologic cancer	0.000747	0.0318	CbGeAlD
Regorafenib—CYP2C8—Ifosfamide—hematologic cancer	0.000736	0.00293	CbGbCtD
Regorafenib—ABCG2—Vincristine—hematologic cancer	0.000721	0.00287	CbGbCtD
Regorafenib—CYP2C19—Thalidomide—hematologic cancer	0.000701	0.0028	CbGbCtD
Regorafenib—ABCG2—Cisplatin—hematologic cancer	0.000672	0.00268	CbGbCtD
Regorafenib—DDR2—hematopoietic system—hematologic cancer	0.00067	0.0285	CbGeAlD
Regorafenib—CYP2C9—Bortezomib—hematologic cancer	0.000669	0.00267	CbGbCtD
Regorafenib—CYP2C19—Teniposide—hematologic cancer	0.000669	0.00267	CbGbCtD
Regorafenib—ABCG2—Etoposide—hematologic cancer	0.00066	0.00263	CbGbCtD
Regorafenib—CYP2C8—Nilotinib—hematologic cancer	0.000639	0.00255	CbGbCtD
Regorafenib—CYP3A4—Bexarotene—hematologic cancer	0.000635	0.00253	CbGbCtD
Regorafenib—ABCB1—Daunorubicin—hematologic cancer	0.000621	0.00248	CbGbCtD
Regorafenib—CYP2C19—Ifosfamide—hematologic cancer	0.000617	0.00246	CbGbCtD
Regorafenib—ABCB1—Alitretinoin—hematologic cancer	0.000609	0.00243	CbGbCtD
Regorafenib—CYP3A4—Lomustine—hematologic cancer	0.00059	0.00235	CbGbCtD
Regorafenib—CYP3A4—Busulfan—hematologic cancer	0.00059	0.00235	CbGbCtD
Regorafenib—CYP2C19—Imatinib—hematologic cancer	0.00059	0.00235	CbGbCtD
Regorafenib—CYP2C9—Thalidomide—hematologic cancer	0.000583	0.00232	CbGbCtD
Regorafenib—CYP2B6—Irinotecan—hematologic cancer	0.00058	0.00231	CbGbCtD
Regorafenib—FRK—gonad—hematologic cancer	0.000568	0.0242	CbGeAlD
Regorafenib—CYP2C9—Teniposide—hematologic cancer	0.000556	0.00222	CbGbCtD
Regorafenib—ABCG2—Dexamethasone—hematologic cancer	0.000543	0.00216	CbGbCtD
Regorafenib—CYP3A4—Thiotepa—hematologic cancer	0.000526	0.0021	CbGbCtD
Regorafenib—CYP2C9—Ifosfamide—hematologic cancer	0.000513	0.00205	CbGbCtD
Regorafenib—NTRK1—testis—hematologic cancer	0.000494	0.021	CbGeAlD
Regorafenib—CYP2C9—Imatinib—hematologic cancer	0.00049	0.00195	CbGbCtD
Regorafenib—ABCB1—Imatinib—hematologic cancer	0.000476	0.0019	CbGbCtD
Regorafenib—CYP2B6—Cisplatin—hematologic cancer	0.000473	0.00188	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—hematologic cancer	0.00045	0.00179	CbGbCtD
Regorafenib—CYP2C9—Nilotinib—hematologic cancer	0.000446	0.00178	CbGbCtD
Regorafenib—ABCG2—Methotrexate—hematologic cancer	0.000436	0.00174	CbGbCtD
Regorafenib—ABCB1—Nilotinib—hematologic cancer	0.000432	0.00172	CbGbCtD
Regorafenib—ABCB1—Vinorelbine—hematologic cancer	0.000429	0.00171	CbGbCtD
Regorafenib—Sorafenib—FLT3—hematologic cancer	0.000424	0.231	CrCbGaD
Regorafenib—FRK—testis—hematologic cancer	0.000409	0.0174	CbGeAlD
Regorafenib—CYP3A4—Methoxsalen—hematologic cancer	0.000409	0.00163	CbGbCtD
Regorafenib—FLT4—hematopoietic system—hematologic cancer	0.000408	0.0174	CbGeAlD
Regorafenib—CYP3A4—Bortezomib—hematologic cancer	0.000389	0.00155	CbGbCtD
Regorafenib—DDR2—lung—hematologic cancer	0.000389	0.0165	CbGeAlD
Regorafenib—CYP2C19—Prednisone—hematologic cancer	0.000389	0.00155	CbGbCtD
Regorafenib—ABCB1—Dasatinib—hematologic cancer	0.000382	0.00152	CbGbCtD
Regorafenib—CYP2B6—Dexamethasone—hematologic cancer	0.000382	0.00152	CbGbCtD
Regorafenib—ABCB1—Mitoxantrone—hematologic cancer	0.000378	0.0015	CbGbCtD
Regorafenib—CYP3A4—Daunorubicin—hematologic cancer	0.000372	0.00148	CbGbCtD
Regorafenib—DDR2—testis—hematologic cancer	0.000367	0.0156	CbGeAlD
Regorafenib—RET—hematopoietic system—hematologic cancer	0.00036	0.0153	CbGeAlD
Regorafenib—CYP2C8—Etoposide—hematologic cancer	0.000352	0.0014	CbGbCtD
Regorafenib—MAPK11—testis—hematologic cancer	0.000348	0.0148	CbGeAlD
Regorafenib—FGFR2—hematopoietic system—hematologic cancer	0.000342	0.0146	CbGeAlD
Regorafenib—ABCB1—Betamethasone—hematologic cancer	0.000337	0.00134	CbGbCtD
Regorafenib—EPHA2—hematopoietic system—hematologic cancer	0.000336	0.0143	CbGeAlD
Regorafenib—ABCB1—Gemcitabine—hematologic cancer	0.000334	0.00133	CbGbCtD
Regorafenib—ABCB1—Prednisolone—hematologic cancer	0.000332	0.00132	CbGbCtD
Regorafenib—CYP3A4—Cytarabine—hematologic cancer	0.000328	0.00131	CbGbCtD
Regorafenib—TEK—hematopoietic system—hematologic cancer	0.000328	0.014	CbGeAlD
Regorafenib—CYP3A4—Teniposide—hematologic cancer	0.000323	0.00129	CbGbCtD
Regorafenib—FLT1—hematopoietic system—hematologic cancer	0.000317	0.0135	CbGeAlD
Regorafenib—CYP2B6—Doxorubicin—hematologic cancer	0.000317	0.00126	CbGbCtD
Regorafenib—RAF1—hematopoietic system—hematologic cancer	0.000315	0.0134	CbGeAlD
Regorafenib—BRAF—blood—hematologic cancer	0.000314	0.0133	CbGeAlD
Regorafenib—ABCB1—Prednisone—hematologic cancer	0.000314	0.00125	CbGbCtD
Regorafenib—BRAF—bone marrow—hematologic cancer	0.000303	0.0129	CbGeAlD
Regorafenib—EPHX2—blood—hematologic cancer	0.0003	0.0128	CbGeAlD
Regorafenib—CYP3A4—Ifosfamide—hematologic cancer	0.000299	0.00119	CbGbCtD
Regorafenib—PDGFRA—hematopoietic system—hematologic cancer	0.000297	0.0126	CbGeAlD
Regorafenib—ABCB1—Irinotecan—hematologic cancer	0.000297	0.00118	CbGbCtD
Regorafenib—RAF1—Topotecan—Irinotecan—hematologic cancer	0.000292	0.289	CbGdCrCtD
Regorafenib—CYP2C8—Dexamethasone—hematologic cancer	0.000289	0.00115	CbGbCtD
Regorafenib—CYP3A4—Imatinib—hematologic cancer	0.000285	0.00114	CbGbCtD
Regorafenib—UGT1A1—hematopoietic system—hematologic cancer	0.000284	0.0121	CbGeAlD
Regorafenib—BRAF—lung—hematologic cancer	0.000275	0.0117	CbGeAlD
Regorafenib—Sorafenib—RET—hematologic cancer	0.000273	0.149	CrCbGaD
Regorafenib—FLT4—blood—hematologic cancer	0.00027	0.0115	CbGeAlD
Regorafenib—CYP3A4—Ruxolitinib—hematologic cancer	0.000269	0.00107	CbGbCtD
Regorafenib—KDR—hematopoietic system—hematologic cancer	0.000268	0.0114	CbGeAlD
Regorafenib—DDR2—lymph node—hematologic cancer	0.000266	0.0113	CbGeAlD
Regorafenib—ABCB1—Vinblastine—hematologic cancer	0.000264	0.00105	CbGbCtD
Regorafenib—EPHX2—lung—hematologic cancer	0.000263	0.0112	CbGeAlD
Regorafenib—FLT4—bone marrow—hematologic cancer	0.000262	0.0111	CbGeAlD
Regorafenib—ABCB1—Vincristine—hematologic cancer	0.00026	0.00104	CbGbCtD
Regorafenib—BRAF—testis—hematologic cancer	0.000259	0.011	CbGeAlD
Regorafenib—CYP3A4—Nilotinib—hematologic cancer	0.000259	0.00103	CbGbCtD
Regorafenib—CYP3A4—Vinorelbine—hematologic cancer	0.000257	0.00102	CbGbCtD
Regorafenib—MAPK11—lymph node—hematologic cancer	0.000252	0.0107	CbGeAlD
Regorafenib—CYP2C9—Cisplatin—hematologic cancer	0.00025	0.000995	CbGbCtD
Regorafenib—EPHX2—testis—hematologic cancer	0.000248	0.0105	CbGeAlD
Regorafenib—CYP2C19—Dexamethasone—hematologic cancer	0.000243	0.000967	CbGbCtD
Regorafenib—ABCB1—Cisplatin—hematologic cancer	0.000242	0.000966	CbGbCtD
Regorafenib—FLT1—gonad—hematologic cancer	0.000241	0.0103	CbGeAlD
Regorafenib—RAF1—gonad—hematologic cancer	0.00024	0.0102	CbGeAlD
Regorafenib—RET—blood—hematologic cancer	0.000239	0.0102	CbGeAlD
Regorafenib—ABCB1—Etoposide—hematologic cancer	0.000238	0.000949	CbGbCtD
Regorafenib—KIT—hematopoietic system—hematologic cancer	0.000238	0.0101	CbGeAlD
Regorafenib—FLT4—lung—hematologic cancer	0.000237	0.0101	CbGeAlD
Regorafenib—CYP3A4—Triamcinolone—hematologic cancer	0.000235	0.000937	CbGbCtD
Regorafenib—FGFR1—lung—hematologic cancer	0.000234	0.00995	CbGeAlD
Regorafenib—PDGFRB—hematopoietic system—hematologic cancer	0.000232	0.00987	CbGeAlD
Regorafenib—CYP3A4—Dasatinib—hematologic cancer	0.000229	0.000913	CbGbCtD
Regorafenib—FGFR2—blood—hematologic cancer	0.000227	0.00965	CbGeAlD
Regorafenib—CYP3A4—Mitoxantrone—hematologic cancer	0.000226	0.000902	CbGbCtD
Regorafenib—PDGFRA—gonad—hematologic cancer	0.000226	0.00962	CbGeAlD
Regorafenib—FLT4—testis—hematologic cancer	0.000224	0.00951	CbGeAlD
Regorafenib—EPHA2—blood—hematologic cancer	0.000223	0.00948	CbGeAlD
Regorafenib—FGFR1—testis—hematologic cancer	0.000221	0.00938	CbGeAlD
Regorafenib—TEK—blood—hematologic cancer	0.000217	0.00925	CbGeAlD
Regorafenib—Sorafenib—CSF1R—hematologic cancer	0.000217	0.118	CrCbGaD
Regorafenib—FLT1—blood—hematologic cancer	0.00021	0.00894	CbGeAlD
Regorafenib—RAF1—blood—hematologic cancer	0.000209	0.00889	CbGeAlD
Regorafenib—ABL1—hematopoietic system—hematologic cancer	0.000207	0.0088	CbGeAlD
Regorafenib—RAF1—bone marrow—hematologic cancer	0.000202	0.0086	CbGeAlD
Regorafenib—CYP2C9—Dexamethasone—hematologic cancer	0.000202	0.000804	CbGbCtD
Regorafenib—CYP3A4—Betamethasone—hematologic cancer	0.000202	0.000804	CbGbCtD
Regorafenib—CYP3A4—Prednisolone—hematologic cancer	0.000199	0.000793	CbGbCtD
Regorafenib—FGFR2—lung—hematologic cancer	0.000199	0.00846	CbGeAlD
Regorafenib—RET—testis—hematologic cancer	0.000197	0.0084	CbGeAlD
Regorafenib—PDGFRA—blood—hematologic cancer	0.000197	0.00838	CbGeAlD
Regorafenib—ABCB1—Dexamethasone—hematologic cancer	0.000196	0.00078	CbGbCtD
Regorafenib—EPHA2—lung—hematologic cancer	0.000195	0.00831	CbGeAlD
Regorafenib—TEK—lung—hematologic cancer	0.000191	0.00811	CbGeAlD
Regorafenib—Sorafenib—PDGFRB—hematologic cancer	0.00019	0.103	CrCbGaD
Regorafenib—BRAF—lymph node—hematologic cancer	0.000188	0.008	CbGeAlD
Regorafenib—UGT1A1—blood—hematologic cancer	0.000188	0.00799	CbGeAlD
Regorafenib—CYP3A4—Prednisone—hematologic cancer	0.000188	0.000749	CbGbCtD
Regorafenib—FGFR2—testis—hematologic cancer	0.000188	0.00798	CbGeAlD
Regorafenib—Sorafenib—PDGFRA—hematologic cancer	0.000185	0.101	CrCbGaD
Regorafenib—EPHA2—testis—hematologic cancer	0.000184	0.00784	CbGeAlD
Regorafenib—FLT1—lung—hematologic cancer	0.000184	0.00784	CbGeAlD
Regorafenib—RAF1—lung—hematologic cancer	0.000183	0.00779	CbGeAlD
Regorafenib—KIT—gonad—hematologic cancer	0.000181	0.00769	CbGeAlD
Regorafenib—TEK—testis—hematologic cancer	0.00018	0.00765	CbGeAlD
Regorafenib—EPHX2—lymph node—hematologic cancer	0.00018	0.00765	CbGeAlD
Regorafenib—CYP3A4—Irinotecan—hematologic cancer	0.000178	0.00071	CbGbCtD
Regorafenib—KDR—blood—hematologic cancer	0.000178	0.00756	CbGeAlD
Regorafenib—PDGFRB—gonad—hematologic cancer	0.000176	0.00751	CbGeAlD
Regorafenib—FLT1—testis—hematologic cancer	0.000174	0.0074	CbGeAlD
Regorafenib—RAF1—testis—hematologic cancer	0.000173	0.00735	CbGeAlD
Regorafenib—PDGFRA—lung—hematologic cancer	0.000173	0.00735	CbGeAlD
Regorafenib—KDR—bone marrow—hematologic cancer	0.000172	0.00731	CbGeAlD
Regorafenib—Sorafenib—BRAF—hematologic cancer	0.000169	0.0921	CrCbGaD
Regorafenib—PDGFRA—testis—hematologic cancer	0.000163	0.00693	CbGeAlD
Regorafenib—ABCB1—Doxorubicin—hematologic cancer	0.000162	0.000647	CbGbCtD
Regorafenib—FLT4—lymph node—hematologic cancer	0.000162	0.0069	CbGeAlD
Regorafenib—FGFR1—lymph node—hematologic cancer	0.00016	0.0068	CbGeAlD
Regorafenib—CYP3A4—Vinblastine—hematologic cancer	0.000158	0.000631	CbGbCtD
Regorafenib—KIT—blood—hematologic cancer	0.000157	0.0067	CbGeAlD
Regorafenib—ABCB1—Methotrexate—hematologic cancer	0.000157	0.000627	CbGbCtD
Regorafenib—ABL1—gonad—hematologic cancer	0.000157	0.00669	CbGeAlD
Regorafenib—KDR—lung—hematologic cancer	0.000156	0.00663	CbGeAlD
Regorafenib—CYP3A4—Vincristine—hematologic cancer	0.000156	0.00062	CbGbCtD
Regorafenib—PDGFRB—blood—hematologic cancer	0.000154	0.00654	CbGeAlD
Regorafenib—CYP2C19—hematopoietic system—hematologic cancer	0.000154	0.00654	CbGeAlD
Regorafenib—KIT—bone marrow—hematologic cancer	0.000152	0.00648	CbGeAlD
Regorafenib—PDGFRB—bone marrow—hematologic cancer	0.000149	0.00633	CbGeAlD
Regorafenib—KDR—testis—hematologic cancer	0.000147	0.00625	CbGeAlD
Regorafenib—RET—lymph node—hematologic cancer	0.000143	0.00609	CbGeAlD
Regorafenib—CYP3A4—Etoposide—hematologic cancer	0.000143	0.000569	CbGbCtD
Regorafenib—KIT—lung—hematologic cancer	0.000138	0.00587	CbGeAlD
Regorafenib—ABL1—blood—hematologic cancer	0.000137	0.00583	CbGeAlD
Regorafenib—Sorafenib—KIT—hematologic cancer	0.000136	0.0739	CrCbGaD
Regorafenib—PDGFRB—lung—hematologic cancer	0.000135	0.00574	CbGeAlD
Regorafenib—CYP2C8—hematopoietic system—hematologic cancer	0.000134	0.00571	CbGeAlD
Regorafenib—EPHA2—lymph node—hematologic cancer	0.000134	0.00568	CbGeAlD
Regorafenib—Sorafenib—UGT1A1—hematologic cancer	0.000134	0.0728	CrCbGaD
Regorafenib—ABL1—bone marrow—hematologic cancer	0.000133	0.00564	CbGeAlD
Regorafenib—TEK—lymph node—hematologic cancer	0.00013	0.00555	CbGeAlD
Regorafenib—KIT—testis—hematologic cancer	0.00013	0.00554	CbGeAlD
Regorafenib—PDGFRB—testis—hematologic cancer	0.000127	0.00541	CbGeAlD
Regorafenib—FLT1—lymph node—hematologic cancer	0.000126	0.00536	CbGeAlD
Regorafenib—RAF1—lymph node—hematologic cancer	0.000125	0.00533	CbGeAlD
Regorafenib—ABL1—Topotecan—Irinotecan—hematologic cancer	0.000121	0.12	CbGdCrCtD
Regorafenib—CYP2B6—hematopoietic system—hematologic cancer	0.00012	0.00512	CbGeAlD
Regorafenib—ABL1—lung—hematologic cancer	0.00012	0.00511	CbGeAlD
Regorafenib—CYP2C9—hematopoietic system—hematologic cancer	0.000119	0.00507	CbGeAlD
Regorafenib—PDGFRA—lymph node—hematologic cancer	0.000118	0.00502	CbGeAlD
Regorafenib—CYP3A4—Dexamethasone—hematologic cancer	0.000117	0.000467	CbGbCtD
Regorafenib—ABL1—testis—hematologic cancer	0.000113	0.00482	CbGeAlD
Regorafenib—KDR—lymph node—hematologic cancer	0.000107	0.00453	CbGeAlD
Regorafenib—CYP2C19—blood—hematologic cancer	0.000102	0.00433	CbGeAlD
Regorafenib—CYP3A4—Doxorubicin—hematologic cancer	9.73e-05	0.000388	CbGbCtD
Regorafenib—KIT—lymph node—hematologic cancer	9.44e-05	0.00402	CbGeAlD
Regorafenib—PDGFRB—lymph node—hematologic cancer	9.22e-05	0.00392	CbGeAlD
Regorafenib—CYP2B6—gonad—hematologic cancer	9.15e-05	0.00389	CbGeAlD
Regorafenib—CYP3A4—hematopoietic system—hematologic cancer	9.09e-05	0.00387	CbGeAlD
Regorafenib—CYP2C8—blood—hematologic cancer	8.89e-05	0.00378	CbGeAlD
Regorafenib—ABCG2—blood—hematologic cancer	8.64e-05	0.00368	CbGeAlD
Regorafenib—ABCG2—bone marrow—hematologic cancer	8.36e-05	0.00356	CbGeAlD
Regorafenib—ABL1—lymph node—hematologic cancer	8.22e-05	0.0035	CbGeAlD
Regorafenib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	8.19e-05	0.0811	CbGdCrCtD
Regorafenib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	8.19e-05	0.0811	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	8.19e-05	0.0811	CbGdCrCtD
Regorafenib—CYP2B6—blood—hematologic cancer	7.97e-05	0.00339	CbGeAlD
Regorafenib—CYP2C9—blood—hematologic cancer	7.9e-05	0.00336	CbGeAlD
Regorafenib—ABCG2—lung—hematologic cancer	7.58e-05	0.00322	CbGeAlD
Regorafenib—Sorafenib—ABCG2—hematologic cancer	7.51e-05	0.0409	CrCbGaD
Regorafenib—CYP2C8—testis—hematologic cancer	7.35e-05	0.00313	CbGeAlD
Regorafenib—ABCG2—testis—hematologic cancer	7.15e-05	0.00304	CbGeAlD
Regorafenib—CYP2B6—lung—hematologic cancer	6.99e-05	0.00297	CbGeAlD
Regorafenib—CYP2B6—testis—hematologic cancer	6.6e-05	0.00281	CbGeAlD
Regorafenib—ABCB1—hematopoietic system—hematologic cancer	6.43e-05	0.00274	CbGeAlD
Regorafenib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	6.21e-05	0.0615	CbGdCrCtD
Regorafenib—ABL1—Epirubicin—Idarubicin—hematologic cancer	6.21e-05	0.0615	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	6.21e-05	0.0615	CbGdCrCtD
Regorafenib—CYP3A4—blood—hematologic cancer	6.02e-05	0.00256	CbGeAlD
Regorafenib—ABCG2—lymph node—hematologic cancer	5.18e-05	0.0022	CbGeAlD
Regorafenib—ABCB1—gonad—hematologic cancer	4.89e-05	0.00208	CbGeAlD
Regorafenib—ABCB1—blood—hematologic cancer	4.26e-05	0.00181	CbGeAlD
Regorafenib—ABCB1—bone marrow—hematologic cancer	4.12e-05	0.00175	CbGeAlD
Regorafenib—ABCB1—lung—hematologic cancer	3.74e-05	0.00159	CbGeAlD
Regorafenib—ABCB1—testis—hematologic cancer	3.53e-05	0.0015	CbGeAlD
Regorafenib—Sorafenib—ABCB1—hematologic cancer	3.12e-05	0.017	CrCbGaD
Regorafenib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	2.85e-05	0.0282	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	2.85e-05	0.0282	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Epirubicin—hematologic cancer	2.85e-05	0.0282	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	2.64e-05	0.0261	CbGdCrCtD
Regorafenib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	2.64e-05	0.0261	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	2.64e-05	0.0261	CbGdCrCtD
Regorafenib—ABCB1—lymph node—hematologic cancer	2.56e-05	0.00109	CbGeAlD
Regorafenib—Dermatitis—Thiotepa—hematologic cancer	1.07e-05	0.000167	CcSEcCtD
Regorafenib—Diarrhoea—Alitretinoin—hematologic cancer	1.07e-05	0.000167	CcSEcCtD
Regorafenib—Headache—Thiotepa—hematologic cancer	1.06e-05	0.000166	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—hematologic cancer	1.06e-05	0.000166	CcSEcCtD
Regorafenib—Hypertension—Dexamethasone—hematologic cancer	1.06e-05	0.000166	CcSEcCtD
Regorafenib—Hypertension—Betamethasone—hematologic cancer	1.06e-05	0.000166	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—hematologic cancer	1.06e-05	0.000166	CcSEcCtD
Regorafenib—Diarrhoea—Ifosfamide—hematologic cancer	1.06e-05	0.000165	CcSEcCtD
Regorafenib—Nausea—Vinorelbine—hematologic cancer	1.06e-05	0.000165	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Etoposide—hematologic cancer	1.05e-05	0.000165	CcSEcCtD
Regorafenib—Body temperature increased—Cisplatin—hematologic cancer	1.05e-05	0.000165	CcSEcCtD
Regorafenib—Asthenia—Mitoxantrone—hematologic cancer	1.05e-05	0.000165	CcSEcCtD
Regorafenib—Asthenia—Irinotecan—hematologic cancer	1.05e-05	0.000165	CcSEcCtD
Regorafenib—Fatigue—Etoposide—hematologic cancer	1.05e-05	0.000164	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—hematologic cancer	1.05e-05	0.000163	CcSEcCtD
Regorafenib—Vomiting—Thalidomide—hematologic cancer	1.04e-05	0.000163	CcSEcCtD
Regorafenib—Pain—Etoposide—hematologic cancer	1.04e-05	0.000163	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—hematologic cancer	1.04e-05	0.000163	CcSEcCtD
Regorafenib—Rash—Thalidomide—hematologic cancer	1.04e-05	0.000162	CcSEcCtD
Regorafenib—Dermatitis—Thalidomide—hematologic cancer	1.04e-05	0.000162	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—hematologic cancer	1.03e-05	0.000162	CcSEcCtD
Regorafenib—Diarrhoea—Vincristine—hematologic cancer	1.03e-05	0.000161	CcSEcCtD
Regorafenib—Headache—Thalidomide—hematologic cancer	1.03e-05	0.000161	CcSEcCtD
Regorafenib—Pain—Prednisolone—hematologic cancer	1.03e-05	0.000161	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—hematologic cancer	1.03e-05	0.000161	CcSEcCtD
Regorafenib—Asthenia—Gemcitabine—hematologic cancer	1.03e-05	0.00016	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—hematologic cancer	1.02e-05	0.000159	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—hematologic cancer	1.01e-05	0.000159	CcSEcCtD
Regorafenib—Nausea—Thiotepa—hematologic cancer	1.01e-05	0.000158	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—hematologic cancer	1.01e-05	0.000158	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—hematologic cancer	1.01e-05	0.000157	CcSEcCtD
Regorafenib—Diarrhoea—Mitoxantrone—hematologic cancer	1e-05	0.000157	CcSEcCtD
Regorafenib—Diarrhoea—Irinotecan—hematologic cancer	1e-05	0.000157	CcSEcCtD
Regorafenib—Vomiting—Carmustine—hematologic cancer	1e-05	0.000157	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—hematologic cancer	9.98e-06	0.000156	CcSEcCtD
Regorafenib—Infection—Betamethasone—hematologic cancer	9.98e-06	0.000156	CcSEcCtD
Regorafenib—Infection—Dexamethasone—hematologic cancer	9.98e-06	0.000156	CcSEcCtD
Regorafenib—Rash—Carmustine—hematologic cancer	9.95e-06	0.000156	CcSEcCtD
Regorafenib—Dermatitis—Carmustine—hematologic cancer	9.94e-06	0.000155	CcSEcCtD
Regorafenib—Vomiting—Alitretinoin—hematologic cancer	9.94e-06	0.000155	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—hematologic cancer	9.93e-06	0.000155	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—hematologic cancer	9.93e-06	0.000155	CcSEcCtD
Regorafenib—Anaemia—Prednisone—hematologic cancer	9.91e-06	0.000155	CcSEcCtD
Regorafenib—Headache—Carmustine—hematologic cancer	9.89e-06	0.000155	CcSEcCtD
Regorafenib—Rash—Alitretinoin—hematologic cancer	9.86e-06	0.000154	CcSEcCtD
Regorafenib—Nervous system disorder—Betamethasone—hematologic cancer	9.85e-06	0.000154	CcSEcCtD
Regorafenib—Nervous system disorder—Dexamethasone—hematologic cancer	9.85e-06	0.000154	CcSEcCtD
Regorafenib—Dermatitis—Alitretinoin—hematologic cancer	9.85e-06	0.000154	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	9.84e-06	0.000154	CcSEcCtD
Regorafenib—Thrombocytopenia—Dexamethasone—hematologic cancer	9.83e-06	0.000154	CcSEcCtD
Regorafenib—Thrombocytopenia—Betamethasone—hematologic cancer	9.83e-06	0.000154	CcSEcCtD
Regorafenib—Vomiting—Ifosfamide—hematologic cancer	9.83e-06	0.000154	CcSEcCtD
Regorafenib—Headache—Alitretinoin—hematologic cancer	9.8e-06	0.000153	CcSEcCtD
Regorafenib—Diarrhoea—Gemcitabine—hematologic cancer	9.78e-06	0.000153	CcSEcCtD
Regorafenib—Nausea—Thalidomide—hematologic cancer	9.76e-06	0.000153	CcSEcCtD
Regorafenib—Rash—Ifosfamide—hematologic cancer	9.74e-06	0.000152	CcSEcCtD
Regorafenib—Dermatitis—Ifosfamide—hematologic cancer	9.73e-06	0.000152	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—hematologic cancer	9.73e-06	0.000152	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—hematologic cancer	9.68e-06	0.000151	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—hematologic cancer	9.67e-06	0.000151	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—hematologic cancer	9.65e-06	0.000151	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—hematologic cancer	9.65e-06	0.000151	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—hematologic cancer	9.63e-06	0.000151	CcSEcCtD
Regorafenib—Vomiting—Vincristine—hematologic cancer	9.58e-06	0.00015	CcSEcCtD
Regorafenib—Asthenia—Cisplatin—hematologic cancer	9.56e-06	0.000149	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—hematologic cancer	9.55e-06	0.000149	CcSEcCtD
Regorafenib—Fatigue—Triamcinolone—hematologic cancer	9.54e-06	0.000149	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—hematologic cancer	9.51e-06	0.000149	CcSEcCtD
Regorafenib—Rash—Vincristine—hematologic cancer	9.5e-06	0.000149	CcSEcCtD
Regorafenib—Dermatitis—Vincristine—hematologic cancer	9.49e-06	0.000148	CcSEcCtD
Regorafenib—Pain—Triamcinolone—hematologic cancer	9.47e-06	0.000148	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—hematologic cancer	9.46e-06	0.000148	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—hematologic cancer	9.44e-06	0.000148	CcSEcCtD
Regorafenib—Headache—Vincristine—hematologic cancer	9.44e-06	0.000148	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—hematologic cancer	9.39e-06	0.000147	CcSEcCtD
Regorafenib—Nausea—Carmustine—hematologic cancer	9.38e-06	0.000147	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—hematologic cancer	9.34e-06	0.000146	CcSEcCtD
Regorafenib—Vomiting—Irinotecan—hematologic cancer	9.33e-06	0.000146	CcSEcCtD
Regorafenib—Vomiting—Mitoxantrone—hematologic cancer	9.33e-06	0.000146	CcSEcCtD
Regorafenib—Nausea—Alitretinoin—hematologic cancer	9.29e-06	0.000145	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—hematologic cancer	9.27e-06	0.000145	CcSEcCtD
Regorafenib—Hypertension—Prednisone—hematologic cancer	9.25e-06	0.000145	CcSEcCtD
Regorafenib—Rash—Mitoxantrone—hematologic cancer	9.25e-06	0.000145	CcSEcCtD
Regorafenib—Rash—Irinotecan—hematologic cancer	9.25e-06	0.000145	CcSEcCtD
Regorafenib—Dermatitis—Irinotecan—hematologic cancer	9.24e-06	0.000144	CcSEcCtD
Regorafenib—Dermatitis—Mitoxantrone—hematologic cancer	9.24e-06	0.000144	CcSEcCtD
Regorafenib—Headache—Mitoxantrone—hematologic cancer	9.19e-06	0.000144	CcSEcCtD
Regorafenib—Headache—Irinotecan—hematologic cancer	9.19e-06	0.000144	CcSEcCtD
Regorafenib—Nausea—Ifosfamide—hematologic cancer	9.18e-06	0.000143	CcSEcCtD
Regorafenib—Diarrhoea—Cisplatin—hematologic cancer	9.12e-06	0.000142	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—hematologic cancer	9.11e-06	0.000142	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—hematologic cancer	9.09e-06	0.000142	CcSEcCtD
Regorafenib—Vomiting—Gemcitabine—hematologic cancer	9.09e-06	0.000142	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	9.06e-06	0.000142	CcSEcCtD
Regorafenib—Rash—Gemcitabine—hematologic cancer	9.01e-06	0.000141	CcSEcCtD
Regorafenib—Dermatitis—Gemcitabine—hematologic cancer	9e-06	0.000141	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—hematologic cancer	8.96e-06	0.00014	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—hematologic cancer	8.96e-06	0.00014	CcSEcCtD
Regorafenib—Headache—Gemcitabine—hematologic cancer	8.95e-06	0.00014	CcSEcCtD
Regorafenib—Nausea—Vincristine—hematologic cancer	8.95e-06	0.00014	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—hematologic cancer	8.94e-06	0.00014	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—hematologic cancer	8.91e-06	0.000139	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—hematologic cancer	8.8e-06	0.000138	CcSEcCtD
Regorafenib—Asthenia—Etoposide—hematologic cancer	8.76e-06	0.000137	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—hematologic cancer	8.76e-06	0.000137	CcSEcCtD
Regorafenib—Body temperature increased—Triamcinolone—hematologic cancer	8.75e-06	0.000137	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—hematologic cancer	8.74e-06	0.000137	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—hematologic cancer	8.73e-06	0.000137	CcSEcCtD
Regorafenib—Decreased appetite—Dexamethasone—hematologic cancer	8.73e-06	0.000136	CcSEcCtD
Regorafenib—Decreased appetite—Betamethasone—hematologic cancer	8.73e-06	0.000136	CcSEcCtD
Regorafenib—Nausea—Irinotecan—hematologic cancer	8.72e-06	0.000136	CcSEcCtD
Regorafenib—Nausea—Mitoxantrone—hematologic cancer	8.72e-06	0.000136	CcSEcCtD
Regorafenib—Infection—Prednisone—hematologic cancer	8.69e-06	0.000136	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—hematologic cancer	8.68e-06	0.000136	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	8.67e-06	0.000136	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Betamethasone—hematologic cancer	8.67e-06	0.000136	CcSEcCtD
Regorafenib—Fatigue—Betamethasone—hematologic cancer	8.66e-06	0.000135	CcSEcCtD
Regorafenib—Fatigue—Dexamethasone—hematologic cancer	8.66e-06	0.000135	CcSEcCtD
Regorafenib—Pain—Dexamethasone—hematologic cancer	8.59e-06	0.000134	CcSEcCtD
Regorafenib—Pain—Betamethasone—hematologic cancer	8.59e-06	0.000134	CcSEcCtD
Regorafenib—Nervous system disorder—Prednisone—hematologic cancer	8.58e-06	0.000134	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—hematologic cancer	8.51e-06	0.000133	CcSEcCtD
Regorafenib—Skin disorder—Prednisone—hematologic cancer	8.5e-06	0.000133	CcSEcCtD
Regorafenib—Nausea—Gemcitabine—hematologic cancer	8.49e-06	0.000133	CcSEcCtD
Regorafenib—Vomiting—Cisplatin—hematologic cancer	8.47e-06	0.000132	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—hematologic cancer	8.42e-06	0.000132	CcSEcCtD
Regorafenib—Rash—Cisplatin—hematologic cancer	8.4e-06	0.000131	CcSEcCtD
Regorafenib—Dermatitis—Cisplatin—hematologic cancer	8.39e-06	0.000131	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—hematologic cancer	8.38e-06	0.000131	CcSEcCtD
Regorafenib—Diarrhoea—Etoposide—hematologic cancer	8.35e-06	0.000131	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—hematologic cancer	8.28e-06	0.000129	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—hematologic cancer	8.27e-06	0.000129	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dexamethasone—hematologic cancer	8.21e-06	0.000128	CcSEcCtD
Regorafenib—Gastrointestinal pain—Betamethasone—hematologic cancer	8.21e-06	0.000128	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—hematologic cancer	8.08e-06	0.000126	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—hematologic cancer	8.03e-06	0.000126	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—hematologic cancer	8.02e-06	0.000125	CcSEcCtD
Regorafenib—Asthenia—Triamcinolone—hematologic cancer	7.94e-06	0.000124	CcSEcCtD
Regorafenib—Abdominal pain—Betamethasone—hematologic cancer	7.94e-06	0.000124	CcSEcCtD
Regorafenib—Body temperature increased—Dexamethasone—hematologic cancer	7.94e-06	0.000124	CcSEcCtD
Regorafenib—Body temperature increased—Betamethasone—hematologic cancer	7.94e-06	0.000124	CcSEcCtD
Regorafenib—Abdominal pain—Dexamethasone—hematologic cancer	7.94e-06	0.000124	CcSEcCtD
Regorafenib—Nausea—Cisplatin—hematologic cancer	7.91e-06	0.000124	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—hematologic cancer	7.87e-06	0.000123	CcSEcCtD
Regorafenib—Vomiting—Etoposide—hematologic cancer	7.76e-06	0.000121	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—hematologic cancer	7.76e-06	0.000121	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—hematologic cancer	7.75e-06	0.000121	CcSEcCtD
Regorafenib—Rash—Etoposide—hematologic cancer	7.7e-06	0.00012	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—hematologic cancer	7.69e-06	0.00012	CcSEcCtD
Regorafenib—Headache—Etoposide—hematologic cancer	7.65e-06	0.00012	CcSEcCtD
Regorafenib—Decreased appetite—Prednisone—hematologic cancer	7.6e-06	0.000119	CcSEcCtD
Regorafenib—Rash—Prednisolone—hematologic cancer	7.59e-06	0.000119	CcSEcCtD
Regorafenib—Dermatitis—Prednisolone—hematologic cancer	7.58e-06	0.000119	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.57e-06	0.000118	CcSEcCtD
Regorafenib—Fatigue—Prednisone—hematologic cancer	7.54e-06	0.000118	CcSEcCtD
Regorafenib—Headache—Prednisolone—hematologic cancer	7.54e-06	0.000118	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—hematologic cancer	7.5e-06	0.000117	CcSEcCtD
Regorafenib—Infection—Methotrexate—hematologic cancer	7.26e-06	0.000114	CcSEcCtD
Regorafenib—Nausea—Etoposide—hematologic cancer	7.25e-06	0.000113	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—hematologic cancer	7.24e-06	0.000113	CcSEcCtD
Regorafenib—Asthenia—Betamethasone—hematologic cancer	7.21e-06	0.000113	CcSEcCtD
Regorafenib—Asthenia—Dexamethasone—hematologic cancer	7.21e-06	0.000113	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—hematologic cancer	7.17e-06	0.000112	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—hematologic cancer	7.17e-06	0.000112	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—hematologic cancer	7.16e-06	0.000112	CcSEcCtD
Regorafenib—Gastrointestinal pain—Prednisone—hematologic cancer	7.15e-06	0.000112	CcSEcCtD
Regorafenib—Nausea—Prednisolone—hematologic cancer	7.15e-06	0.000112	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—hematologic cancer	7.1e-06	0.000111	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	7.09e-06	0.000111	CcSEcCtD
Regorafenib—Vomiting—Triamcinolone—hematologic cancer	7.04e-06	0.00011	CcSEcCtD
Regorafenib—Rash—Triamcinolone—hematologic cancer	6.98e-06	0.000109	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—hematologic cancer	6.98e-06	0.000109	CcSEcCtD
Regorafenib—Dermatitis—Triamcinolone—hematologic cancer	6.97e-06	0.000109	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—hematologic cancer	6.94e-06	0.000109	CcSEcCtD
Regorafenib—Headache—Triamcinolone—hematologic cancer	6.94e-06	0.000108	CcSEcCtD
Regorafenib—Abdominal pain—Prednisone—hematologic cancer	6.92e-06	0.000108	CcSEcCtD
Regorafenib—Body temperature increased—Prednisone—hematologic cancer	6.92e-06	0.000108	CcSEcCtD
Regorafenib—Diarrhoea—Dexamethasone—hematologic cancer	6.87e-06	0.000107	CcSEcCtD
Regorafenib—Diarrhoea—Betamethasone—hematologic cancer	6.87e-06	0.000107	CcSEcCtD
Regorafenib—Infection—Epirubicin—hematologic cancer	6.8e-06	0.000106	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—hematologic cancer	6.71e-06	0.000105	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—hematologic cancer	6.7e-06	0.000105	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—hematologic cancer	6.7e-06	0.000105	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—hematologic cancer	6.65e-06	0.000104	CcSEcCtD
Regorafenib—Nausea—Triamcinolone—hematologic cancer	6.58e-06	0.000103	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.56e-06	0.000103	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—hematologic cancer	6.46e-06	0.000101	CcSEcCtD
Regorafenib—Vomiting—Betamethasone—hematologic cancer	6.39e-06	9.98e-05	CcSEcCtD
Regorafenib—Vomiting—Dexamethasone—hematologic cancer	6.39e-06	9.98e-05	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—hematologic cancer	6.36e-06	9.93e-05	CcSEcCtD
Regorafenib—Rash—Betamethasone—hematologic cancer	6.33e-06	9.9e-05	CcSEcCtD
Regorafenib—Rash—Dexamethasone—hematologic cancer	6.33e-06	9.9e-05	CcSEcCtD
Regorafenib—Dermatitis—Dexamethasone—hematologic cancer	6.33e-06	9.89e-05	CcSEcCtD
Regorafenib—Dermatitis—Betamethasone—hematologic cancer	6.33e-06	9.89e-05	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—hematologic cancer	6.31e-06	9.87e-05	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—hematologic cancer	6.3e-06	9.85e-05	CcSEcCtD
Regorafenib—Headache—Dexamethasone—hematologic cancer	6.29e-06	9.84e-05	CcSEcCtD
Regorafenib—Headache—Betamethasone—hematologic cancer	6.29e-06	9.84e-05	CcSEcCtD
Regorafenib—Infection—Doxorubicin—hematologic cancer	6.29e-06	9.83e-05	CcSEcCtD
Regorafenib—Asthenia—Prednisone—hematologic cancer	6.28e-06	9.81e-05	CcSEcCtD
Regorafenib—Pain—Methotrexate—hematologic cancer	6.25e-06	9.77e-05	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—hematologic cancer	6.21e-06	9.7e-05	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—hematologic cancer	6.2e-06	9.69e-05	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—hematologic cancer	6.15e-06	9.61e-05	CcSEcCtD
Regorafenib—Diarrhoea—Prednisone—hematologic cancer	5.99e-06	9.36e-05	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—hematologic cancer	5.98e-06	9.35e-05	CcSEcCtD
Regorafenib—Nausea—Betamethasone—hematologic cancer	5.97e-06	9.33e-05	CcSEcCtD
Regorafenib—Nausea—Dexamethasone—hematologic cancer	5.97e-06	9.33e-05	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—hematologic cancer	5.95e-06	9.3e-05	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.91e-06	9.23e-05	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—hematologic cancer	5.9e-06	9.22e-05	CcSEcCtD
Regorafenib—Pain—Epirubicin—hematologic cancer	5.85e-06	9.15e-05	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—hematologic cancer	5.78e-06	9.03e-05	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—hematologic cancer	5.78e-06	9.03e-05	CcSEcCtD
Regorafenib—Gastrointestinal pain—Epirubicin—hematologic cancer	5.59e-06	8.75e-05	CcSEcCtD
Regorafenib—Vomiting—Prednisone—hematologic cancer	5.56e-06	8.69e-05	CcSEcCtD
Regorafenib—Rash—Prednisone—hematologic cancer	5.52e-06	8.62e-05	CcSEcCtD
Regorafenib—Dermatitis—Prednisone—hematologic cancer	5.51e-06	8.61e-05	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—hematologic cancer	5.5e-06	8.6e-05	CcSEcCtD
Regorafenib—Headache—Prednisone—hematologic cancer	5.48e-06	8.57e-05	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.47e-06	8.54e-05	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—hematologic cancer	5.46e-06	8.53e-05	CcSEcCtD
Regorafenib—Pain—Doxorubicin—hematologic cancer	5.41e-06	8.46e-05	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—hematologic cancer	5.41e-06	8.45e-05	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—hematologic cancer	5.41e-06	8.45e-05	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—hematologic cancer	5.25e-06	8.2e-05	CcSEcCtD
Regorafenib—Nausea—Prednisone—hematologic cancer	5.2e-06	8.12e-05	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.18e-06	8.09e-05	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—hematologic cancer	5e-06	7.82e-05	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—hematologic cancer	5e-06	7.82e-05	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—hematologic cancer	5e-06	7.82e-05	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—hematologic cancer	4.91e-06	7.67e-05	CcSEcCtD
Regorafenib—Diarrhoea—Epirubicin—hematologic cancer	4.68e-06	7.32e-05	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—hematologic cancer	4.65e-06	7.27e-05	CcSEcCtD
Regorafenib—Rash—Methotrexate—hematologic cancer	4.61e-06	7.21e-05	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—hematologic cancer	4.61e-06	7.2e-05	CcSEcCtD
Regorafenib—Headache—Methotrexate—hematologic cancer	4.58e-06	7.16e-05	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—hematologic cancer	4.54e-06	7.1e-05	CcSEcCtD
Regorafenib—Vomiting—Epirubicin—hematologic cancer	4.35e-06	6.8e-05	CcSEcCtD
Regorafenib—Nausea—Methotrexate—hematologic cancer	4.34e-06	6.79e-05	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—hematologic cancer	4.33e-06	6.77e-05	CcSEcCtD
Regorafenib—Rash—Epirubicin—hematologic cancer	4.31e-06	6.74e-05	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—hematologic cancer	4.31e-06	6.74e-05	CcSEcCtD
Regorafenib—Headache—Epirubicin—hematologic cancer	4.29e-06	6.7e-05	CcSEcCtD
Regorafenib—Nausea—Epirubicin—hematologic cancer	4.06e-06	6.35e-05	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—hematologic cancer	4.02e-06	6.29e-05	CcSEcCtD
Regorafenib—Rash—Doxorubicin—hematologic cancer	3.99e-06	6.24e-05	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—hematologic cancer	3.99e-06	6.23e-05	CcSEcCtD
Regorafenib—Headache—Doxorubicin—hematologic cancer	3.97e-06	6.2e-05	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—hematologic cancer	3.76e-06	5.88e-05	CcSEcCtD
Regorafenib—BRAF—Disease—AKT1—hematologic cancer	1.89e-07	2.88e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MDM2—hematologic cancer	1.89e-07	2.88e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—hematologic cancer	1.89e-07	2.88e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EP300—hematologic cancer	1.89e-07	2.88e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—hematologic cancer	1.89e-07	2.88e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—hematologic cancer	1.89e-07	2.88e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—TGFB1—hematologic cancer	1.89e-07	2.87e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.88e-07	2.87e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—hematologic cancer	1.87e-07	2.85e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTM1—hematologic cancer	1.87e-07	2.85e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NCOR1—hematologic cancer	1.87e-07	2.85e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NRAS—hematologic cancer	1.87e-07	2.85e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—hematologic cancer	1.87e-07	2.85e-06	CbGpPWpGaD
Regorafenib—KIT—Immune System—AKT1—hematologic cancer	1.87e-07	2.84e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—EP300—hematologic cancer	1.87e-07	2.84e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—EP300—hematologic cancer	1.87e-07	2.84e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—hematologic cancer	1.87e-07	2.84e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTR—hematologic cancer	1.86e-07	2.83e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.86e-07	2.83e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.86e-07	2.83e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—hematologic cancer	1.85e-07	2.82e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.85e-07	2.82e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—hematologic cancer	1.85e-07	2.82e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—hematologic cancer	1.85e-07	2.81e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JUN—hematologic cancer	1.85e-07	2.81e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—hematologic cancer	1.84e-07	2.81e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SRC—hematologic cancer	1.84e-07	2.81e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MTOR—hematologic cancer	1.84e-07	2.81e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CB—hematologic cancer	1.84e-07	2.81e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SRC—hematologic cancer	1.84e-07	2.8e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CG—hematologic cancer	1.84e-07	2.8e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NCOR1—hematologic cancer	1.83e-07	2.78e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTM1—hematologic cancer	1.83e-07	2.78e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK3—hematologic cancer	1.82e-07	2.78e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO2—hematologic cancer	1.82e-07	2.77e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—hematologic cancer	1.8e-07	2.75e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—hematologic cancer	1.8e-07	2.74e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.8e-07	2.74e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—hematologic cancer	1.8e-07	2.73e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—hematologic cancer	1.79e-07	2.73e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1A—hematologic cancer	1.79e-07	2.73e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK3—hematologic cancer	1.79e-07	2.73e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—hematologic cancer	1.79e-07	2.72e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—hematologic cancer	1.79e-07	2.72e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—hematologic cancer	1.78e-07	2.72e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—hematologic cancer	1.78e-07	2.71e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—hematologic cancer	1.77e-07	2.7e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—hematologic cancer	1.77e-07	2.7e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—hematologic cancer	1.77e-07	2.7e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—hematologic cancer	1.77e-07	2.7e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—hematologic cancer	1.77e-07	2.7e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—hematologic cancer	1.77e-07	2.69e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—hematologic cancer	1.77e-07	2.69e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFB1—hematologic cancer	1.77e-07	2.69e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—hematologic cancer	1.77e-07	2.69e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—hematologic cancer	1.77e-07	2.69e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.77e-07	2.69e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—hematologic cancer	1.76e-07	2.69e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—hematologic cancer	1.76e-07	2.68e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.76e-07	2.68e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—hematologic cancer	1.76e-07	2.68e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—hematologic cancer	1.76e-07	2.67e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK8—hematologic cancer	1.75e-07	2.66e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—hematologic cancer	1.75e-07	2.66e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—hematologic cancer	1.74e-07	2.65e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—hematologic cancer	1.74e-07	2.65e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFB1—hematologic cancer	1.74e-07	2.64e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—hematologic cancer	1.73e-07	2.63e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SDC1—hematologic cancer	1.73e-07	2.63e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—hematologic cancer	1.73e-07	2.63e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—hematologic cancer	1.72e-07	2.63e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.71e-07	2.6e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.71e-07	2.6e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CREBBP—hematologic cancer	1.71e-07	2.6e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EP300—hematologic cancer	1.7e-07	2.59e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK3—hematologic cancer	1.7e-07	2.59e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—hematologic cancer	1.7e-07	2.58e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK3—hematologic cancer	1.69e-07	2.58e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—hematologic cancer	1.69e-07	2.58e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—hematologic cancer	1.69e-07	2.57e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—hematologic cancer	1.68e-07	2.56e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—hematologic cancer	1.68e-07	2.56e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—hematologic cancer	1.67e-07	2.54e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—hematologic cancer	1.66e-07	2.53e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SRC—hematologic cancer	1.66e-07	2.52e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.65e-07	2.52e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—hematologic cancer	1.65e-07	2.52e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—hematologic cancer	1.65e-07	2.51e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFB1—hematologic cancer	1.65e-07	2.51e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—hematologic cancer	1.65e-07	2.51e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—hematologic cancer	1.65e-07	2.51e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—hematologic cancer	1.65e-07	2.51e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFB1—hematologic cancer	1.64e-07	2.5e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—hematologic cancer	1.64e-07	2.5e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—hematologic cancer	1.64e-07	2.49e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—hematologic cancer	1.64e-07	2.49e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.63e-07	2.49e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—hematologic cancer	1.63e-07	2.48e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—hematologic cancer	1.62e-07	2.47e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CD—hematologic cancer	1.62e-07	2.46e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—hematologic cancer	1.61e-07	2.46e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—hematologic cancer	1.61e-07	2.46e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—hematologic cancer	1.61e-07	2.45e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—hematologic cancer	1.61e-07	2.45e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—hematologic cancer	1.6e-07	2.44e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—hematologic cancer	1.6e-07	2.43e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1A—hematologic cancer	1.6e-07	2.43e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—hematologic cancer	1.6e-07	2.43e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—hematologic cancer	1.59e-07	2.43e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—hematologic cancer	1.59e-07	2.43e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—hematologic cancer	1.59e-07	2.42e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—hematologic cancer	1.59e-07	2.42e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—hematologic cancer	1.59e-07	2.41e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—EP300—hematologic cancer	1.58e-07	2.41e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—hematologic cancer	1.57e-07	2.39e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK8—hematologic cancer	1.56e-07	2.37e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—hematologic cancer	1.56e-07	2.37e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.56e-07	2.37e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—hematologic cancer	1.55e-07	2.37e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—hematologic cancer	1.55e-07	2.36e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—hematologic cancer	1.54e-07	2.34e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—hematologic cancer	1.53e-07	2.32e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3R1—hematologic cancer	1.53e-07	2.32e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK3—hematologic cancer	1.53e-07	2.32e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—hematologic cancer	1.52e-07	2.32e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EP300—hematologic cancer	1.52e-07	2.31e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—hematologic cancer	1.52e-07	2.31e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.51e-07	2.3e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—hematologic cancer	1.51e-07	2.29e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—hematologic cancer	1.5e-07	2.29e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—hematologic cancer	1.48e-07	2.26e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—hematologic cancer	1.48e-07	2.26e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFB1—hematologic cancer	1.48e-07	2.26e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—hematologic cancer	1.48e-07	2.25e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SRC—hematologic cancer	1.48e-07	2.25e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—hematologic cancer	1.47e-07	2.24e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NQO1—hematologic cancer	1.47e-07	2.24e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CD44—hematologic cancer	1.47e-07	2.24e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.46e-07	2.22e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—hematologic cancer	1.46e-07	2.22e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—hematologic cancer	1.45e-07	2.21e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CREBBP—hematologic cancer	1.44e-07	2.2e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—hematologic cancer	1.44e-07	2.19e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—hematologic cancer	1.44e-07	2.19e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—hematologic cancer	1.43e-07	2.18e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—hematologic cancer	1.42e-07	2.17e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—hematologic cancer	1.42e-07	2.16e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—hematologic cancer	1.42e-07	2.16e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—hematologic cancer	1.42e-07	2.16e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CB—hematologic cancer	1.41e-07	2.15e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—hematologic cancer	1.4e-07	2.14e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—hematologic cancer	1.4e-07	2.13e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—hematologic cancer	1.39e-07	2.12e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.39e-07	2.12e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYCS—hematologic cancer	1.39e-07	2.12e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—hematologic cancer	1.38e-07	2.1e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—hematologic cancer	1.38e-07	2.1e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.38e-07	2.1e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—hematologic cancer	1.37e-07	2.09e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.37e-07	2.08e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—hematologic cancer	1.37e-07	2.08e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK3—hematologic cancer	1.36e-07	2.07e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—hematologic cancer	1.36e-07	2.07e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.36e-07	2.07e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—hematologic cancer	1.35e-07	2.06e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—hematologic cancer	1.35e-07	2.06e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—hematologic cancer	1.34e-07	2.04e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—hematologic cancer	1.33e-07	2.03e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.33e-07	2.02e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—hematologic cancer	1.33e-07	2.02e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—hematologic cancer	1.32e-07	2.01e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFB1—hematologic cancer	1.32e-07	2.01e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—hematologic cancer	1.31e-07	2e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—hematologic cancer	1.31e-07	1.99e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—hematologic cancer	1.3e-07	1.98e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—hematologic cancer	1.29e-07	1.97e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3R1—hematologic cancer	1.29e-07	1.97e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.29e-07	1.96e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.27e-07	1.93e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—hematologic cancer	1.26e-07	1.92e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CREBBP—hematologic cancer	1.26e-07	1.91e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—hematologic cancer	1.24e-07	1.89e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—hematologic cancer	1.24e-07	1.89e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—hematologic cancer	1.23e-07	1.87e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.22e-07	1.86e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—hematologic cancer	1.22e-07	1.86e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.22e-07	1.86e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—hematologic cancer	1.22e-07	1.86e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—hematologic cancer	1.22e-07	1.85e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—hematologic cancer	1.21e-07	1.84e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—hematologic cancer	1.21e-07	1.84e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CB—hematologic cancer	1.19e-07	1.82e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.19e-07	1.82e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—hematologic cancer	1.18e-07	1.79e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.17e-07	1.79e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—hematologic cancer	1.17e-07	1.78e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—hematologic cancer	1.17e-07	1.78e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—EP300—hematologic cancer	1.16e-07	1.77e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.16e-07	1.77e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.15e-07	1.76e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—hematologic cancer	1.15e-07	1.74e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—hematologic cancer	1.14e-07	1.74e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—hematologic cancer	1.13e-07	1.72e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—hematologic cancer	1.13e-07	1.72e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.13e-07	1.71e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.13e-07	1.71e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.13e-07	1.71e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—hematologic cancer	1.12e-07	1.71e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—hematologic cancer	1.12e-07	1.7e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.11e-07	1.7e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—hematologic cancer	1.1e-07	1.67e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—hematologic cancer	1.09e-07	1.65e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.06e-07	1.62e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.05e-07	1.6e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—hematologic cancer	1.04e-07	1.58e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.04e-07	1.58e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—hematologic cancer	1.03e-07	1.57e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—hematologic cancer	1.03e-07	1.57e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—hematologic cancer	9.95e-08	1.51e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—hematologic cancer	9.95e-08	1.51e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—EP300—hematologic cancer	9.83e-08	1.5e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CB—hematologic cancer	9.71e-08	1.48e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—hematologic cancer	9.57e-08	1.46e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—hematologic cancer	9.2e-08	1.4e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—hematologic cancer	9.18e-08	1.4e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—hematologic cancer	8.98e-08	1.37e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—EP300—hematologic cancer	8.78e-08	1.34e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—hematologic cancer	8.59e-08	1.31e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—EP300—hematologic cancer	8.57e-08	1.3e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—hematologic cancer	8.39e-08	1.28e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	8.36e-08	1.27e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—EP300—hematologic cancer	8e-08	1.22e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CREBBP—hematologic cancer	7.75e-08	1.18e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	7.35e-08	1.12e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—hematologic cancer	7.27e-08	1.11e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—hematologic cancer	7.25e-08	1.1e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—hematologic cancer	7.02e-08	1.07e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	6.94e-08	1.06e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—hematologic cancer	6.49e-08	9.88e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	6.4e-08	9.75e-07	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—hematologic cancer	6.34e-08	9.65e-07	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—hematologic cancer	5.94e-08	9.05e-07	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—hematologic cancer	5.92e-08	9.01e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—hematologic cancer	5.53e-08	8.42e-07	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—hematologic cancer	5.3e-08	8.07e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—EP300—hematologic cancer	5.28e-08	8.03e-07	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—hematologic cancer	5.18e-08	7.88e-07	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—hematologic cancer	4.84e-08	7.36e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.9e-08	5.94e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—hematologic cancer	3.19e-08	4.86e-07	CbGpPWpGaD
